tetano
Editor, Senior Moderator
Int Immunopharmacol
. 2023 Feb 27;117:109934.
doi: 10.1016/j.intimp.2023.109934. Online ahead of print.
An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations
Mona Sadat Mirtaleb[SUP] 1 [/SUP], Reza Falak[SUP] 2 [/SUP], Jalal Heshmatnia[SUP] 3 [/SUP], Behnaz Bakhshandeh[SUP] 4 [/SUP], Ramezan Ali Taheri[SUP] 5 [/SUP], Hoorieh Soleimanjahi[SUP] 6 [/SUP], Reza Zolfaghari Emameh[SUP] 7 [/SUP]
Affiliations
Abstract
The worldwide spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has urged scientists to present some novel vaccine platforms during this pandemic to provide a rather prolonged immunity against this respiratory viral infection. In spite of many campaigns formed against the administration of mRNA-based vaccines, those platforms were the most novel types, which helped us meet the global demand by developing protection against COVID-19 and reducing the development of severe forms of this respiratory viral infection. Some societies are worry about the COVID-19 mRNA vaccine administration and the potential risk of genetic integration of inoculated mRNA into the human genome. Although the efficacy and long-term safety of mRNA vaccines have not yet been fully clarified, obviously their application has switched the mortality and morbidity of the COVID-19 pandemic. This study describes the structural features and technologies used in producing of COVID-19 mRNA-based vaccines as the most influential factor in controlling this pandemic and a successful pattern for planning to produce other kind of genetic vaccines against infections or cancers.
Keywords: Horizontal gene transfer (HGT); Immunization; SARS-CoV-2; Vaccination; mRNA-based Vaccine.
. 2023 Feb 27;117:109934.
doi: 10.1016/j.intimp.2023.109934. Online ahead of print.
An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations
Mona Sadat Mirtaleb[SUP] 1 [/SUP], Reza Falak[SUP] 2 [/SUP], Jalal Heshmatnia[SUP] 3 [/SUP], Behnaz Bakhshandeh[SUP] 4 [/SUP], Ramezan Ali Taheri[SUP] 5 [/SUP], Hoorieh Soleimanjahi[SUP] 6 [/SUP], Reza Zolfaghari Emameh[SUP] 7 [/SUP]
Affiliations
- PMID: 36867924
- PMCID: PMC9968612
- DOI: 10.1016/j.intimp.2023.109934
Abstract
The worldwide spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has urged scientists to present some novel vaccine platforms during this pandemic to provide a rather prolonged immunity against this respiratory viral infection. In spite of many campaigns formed against the administration of mRNA-based vaccines, those platforms were the most novel types, which helped us meet the global demand by developing protection against COVID-19 and reducing the development of severe forms of this respiratory viral infection. Some societies are worry about the COVID-19 mRNA vaccine administration and the potential risk of genetic integration of inoculated mRNA into the human genome. Although the efficacy and long-term safety of mRNA vaccines have not yet been fully clarified, obviously their application has switched the mortality and morbidity of the COVID-19 pandemic. This study describes the structural features and technologies used in producing of COVID-19 mRNA-based vaccines as the most influential factor in controlling this pandemic and a successful pattern for planning to produce other kind of genetic vaccines against infections or cancers.
Keywords: Horizontal gene transfer (HGT); Immunization; SARS-CoV-2; Vaccination; mRNA-based Vaccine.